Rhinovirus is the most common cause of the common cold, responsible for more upper respiratory infections than any other pathogen. It belongs to the enterovirus genus within a family of small RNA viruses, and it comes in three species (A, B, and C) with at least 174 distinct types identified so far. That staggering variety is a big part of why you keep catching colds year after year, and why there’s still no vaccine.
How the Virus Is Built
Rhinovirus is tiny and structurally simple. It carries a single strand of RNA, roughly 7,200 genetic bases long, wrapped inside a protein shell called a capsid. The capsid is made of 60 identical building blocks, each assembled from four proteins. Three of these proteins sit on the outer surface and determine how the virus interacts with your cells. The fourth lines the inside, acting as a bridge between the outer shell and the genetic material within. Unlike flu viruses, rhinovirus has no outer lipid envelope, which makes it resistant to many disinfectants that work by dissolving fatty coatings.
How It Gets Into Your Cells
Most rhinovirus types latch onto a molecule called ICAM-1, a protein found on the surface of cells lining your nose and throat. ICAM-1 normally helps your immune cells communicate, but rhinovirus hijacks it as a doorway. Once the virus binds, it’s pulled inside the cell, where it sheds its protein shell and releases its RNA. That RNA immediately gets to work, using your cell’s own machinery to produce thousands of new virus copies within hours. Those copies burst out and infect neighboring cells, spreading the infection through the upper airway.
What It Feels Like
Rhinovirus infections usually stay in the nose and throat, producing the familiar pattern of a runny nose, sneezing, sore throat, and mild cough. Symptoms typically last less than 7 days, though they can drag on for up to 2 weeks. Fever is uncommon in adults but shows up more often in young children. Compared to flu, rhinovirus infections are milder and rarely cause the deep fatigue or body aches that send people to bed for days.
Who Gets Sick Most Often
Children are rhinovirus magnets. The average child catches 8 to 12 colds per year, mostly because their immune systems haven’t encountered enough types to build up partial protection. Adults fare better, averaging two to three colds annually, with each exposure adding to a growing (but incomplete) library of immunity against specific types.
Seasonal Patterns
Unlike flu, which has one clear winter peak, rhinovirus circulates in multiple waves throughout the year. In temperate climates, infections spike in early fall, shortly after children return to school, and again in spring. One well-documented pattern: asthma-related emergency visits in children surge during the first week of September in North America, driven largely by rhinovirus spreading through classrooms. In tropical regions, the seasonal picture is less predictable. A study in Hawaii found positive samples peaking across scattered months, with lower wind speed being the only weather variable significantly linked to higher detection rates.
Rhinovirus and Chronic Lung Disease
For most healthy people, rhinovirus is a nuisance. For people with asthma or chronic obstructive pulmonary disease (COPD), it can be genuinely dangerous. Viral infections are the most common trigger of flare-ups in both conditions, and rhinovirus is the dominant culprit. Studies of children hospitalized for acute asthma attacks have found rhinovirus in as many as 82% of cases. Among outpatient children with asthma flare-ups, 62 to 81% test positive for a virus, compared to just 12 to 41% of children who are well.
What makes this puzzling is that rhinovirus infects relatively few cells in the airway and doesn’t destroy tissue the way influenza or RSV does. Instead, the damage appears to come from an exaggerated inflammatory response in airways that are already hypersensitive. The virus essentially trips an alarm system that overreacts, narrowing airways and producing excess mucus far out of proportion to the actual infection.
How It’s Diagnosed
Most rhinovirus infections are never formally diagnosed. If you have a cold, your doctor will generally treat it based on symptoms alone. When identification matters, such as in hospitalized patients or research settings, PCR-based testing is the standard approach. Older methods like growing the virus in cell cultures are slow and require specialized expertise, so they’ve been largely replaced by molecular tests that can identify the specific virus type within hours. These tests are most commonly used in situations where distinguishing rhinovirus from other respiratory viruses would change how a patient is managed.
Why There’s No Vaccine
The sheer number of rhinovirus types is the central obstacle. With 174 known types spread across three species, each with a differently shaped surface, the immune response you build after one infection does almost nothing to protect you against the next type you encounter. Antibodies generated by a natural rhinovirus infection are type-specific and often short-lived, unlike measles immunity, which lasts a lifetime after a single exposure.
This creates a cascade of problems for vaccine designers. A successful vaccine would need to provoke a broad immune response covering many types simultaneously, but researchers still don’t fully understand which immune responses actually provide cross-type protection. It’s unclear whether the key lies in antibodies, immune memory cells, or mucosal defenses in the nose and throat. On top of that, there are no good animal models that reliably mimic how rhinovirus behaves in humans, making it difficult to test candidates before moving to human trials.
Spread and Prevention
Rhinovirus spreads through respiratory droplets when an infected person coughs, sneezes, or talks, and through contact with contaminated surfaces. The relative importance of airborne versus surface transmission remains genuinely uncertain. Research has established that both routes are plausible, but the contribution of each in real-world settings is still not well quantified.
Without a vaccine, prevention comes down to basics: frequent handwashing, avoiding touching your face, and staying away from close contact with people who are actively symptomatic. Treatment remains supportive. Rest, fluids, and over-the-counter symptom relief are the standard approach. Antibiotics do nothing against rhinovirus or any other virus, and no antiviral medication is currently approved for routine use against it.